Skip to main
LCTX
LCTX logo

LCTX Stock Forecast & Price Target

LCTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lineage Cell Therapeutics Inc. has achieved a significant milestone with a $5 million payment from Roche, reflecting advances in manufacturing and clinical progress for its OpRegen therapy, targeting geographic atrophy associated with age-related macular degeneration. The promising early data on OpRegen suggests potential for vision reversal, which may differentiate it from currently approved treatments that primarily slow disease progression. Additionally, the ongoing advancements in Lineage’s ReSonance program, alongside the efficient allocation of resources to secure intellectual property, indicate a strong foundation for future growth across multiple therapeutic indications.

Bears say

Lineage Cell Therapeutics faces significant financial risks due to the potential for failed or inconclusive clinical trials, which could hinder the progress of its drug candidates through development. Additionally, the company may encounter challenges in securing adequate funding necessary for advancing its pipeline, exacerbating uncertainties around its financial stability. The inherent risks associated with the regenerative medicine sector further compound the negative outlook on the company's stock.

LCTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lineage Cell Therapeutics Inc (LCTX) Forecast

Analysts have given LCTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, LCTX has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lineage Cell Therapeutics Inc (LCTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.